Morgan Stanley Adc Therapeutics Sa Transaction History

Morgan Stanley

$1.36 Trillion
Q1 2025

A detailed history of Morgan Stanley transactions in Adc Therapeutics Sa stock. As of the latest transaction made, Morgan Stanley holds 3,019,585 shares of ADCT stock, worth $10.4 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

3,019,585

Previous 3,956,172 23.67%

Holding current value

$10.4 Million

Previous $7.87 Million 45.92%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$1.39 - $2.02 $1.3 Million - $1.89 Million	-936,587 Reduced 23.67%	3,019,585 $4.26 Million
Q4 2024 Feb 14, 2025	BUY	$1.89 - $3.48 $1.73 Million - $3.19 Million	915,378 Added 30.1%	3,956,172 $7.87 Million
Q3 2024 May 14, 2025	BUY	$2.59 - $4.01 $195,713 - $303,015	75,565 Added 2.55%	3,040,794 $9.58 Million
Q3 2024 Nov 14, 2024	BUY	$2.59 - $4.01 $195,713 - $303,015	75,565 Added 2.55%	3,040,794 $9.58 Million
Q2 2024 May 14, 2025	SELL	$2.55 - $5.09 $2.53 Million - $5.04 Million	-990,943 Reduced 25.05%	2,965,229 $9.37 Million
Q2 2024 Oct 17, 2024	BUY	$2.55 - $5.09 $624,326 - $1.25 Million	244,834 Added 9.0%	2,965,229 $9.37 Million
Q2 2024 Aug 14, 2024	BUY	$2.55 - $5.09 $624,326 - $1.25 Million	244,834 Added 9.0%	2,965,229 $9.37 Million
Q1 2024 Oct 17, 2024	SELL	$1.66 - $5.29 $406,424 - $1.3 Million	-244,834 Reduced 8.26%	2,720,395 $12.2 Million
Q1 2024 Aug 16, 2024	BUY	$1.66 - $5.29 $3.22 Million - $10.3 Million	1,938,458 Added 247.9%	2,720,395 $12.2 Million
Q1 2024 May 15, 2024	BUY	$1.66 - $5.29 $3.22 Million - $10.3 Million	1,938,458 Added 247.9%	2,720,395 $12.2 Million
Q4 2023 Aug 16, 2024	SELL	$0.47 - $1.79 $1.03 Million - $3.91 Million	-2,183,292 Reduced 73.63%	781,937 $1.3 Million
Q4 2023 Feb 13, 2024	BUY	$0.47 - $1.79 $55,417 - $211,058	117,910 Added 17.76%	781,937 $1.3 Million
Q3 2023 Nov 15, 2023	BUY	$0.72 - $2.37 $8,099 - $26,660	11,249 Added 1.72%	664,027 $597,000
Q2 2023 Aug 14, 2023	BUY	$1.9 - $2.66 $408,175 - $571,445	214,829 Added 49.05%	652,778 $1.4 Million
Q1 2023 May 15, 2023	BUY	$1.92 - $5.45 $167,377 - $475,109	87,176 Added 24.85%	437,949 $854,000
Q4 2022 Feb 14, 2023	BUY	$2.87 - $5.24 $194,474 - $355,067	67,761 Added 23.94%	350,773 $1.35 Million
Q3 2022 Nov 14, 2022	BUY	$4.66 - $10.31 $360,889 - $798,447	77,444 Added 37.67%	283,012 $1.37 Million
Q2 2022 Oct 27, 2022	BUY	$5.96 - $14.99 $713,429 - $1.79 Million	119,703 Added 139.41%	205,568 $1.63 Million
Q2 2022 Aug 15, 2022	BUY	$5.96 - $14.99 $713,429 - $1.79 Million	119,703 Added 139.41%	205,568 $1.63 Million
Q1 2022 Oct 27, 2022	SELL	$13.28 - $20.03 $1.59 Million - $2.4 Million	-119,703 Reduced 58.23%	85,865 $1.26 Million
Q1 2022 May 13, 2022	BUY	$13.28 - $20.03 $199,492 - $300,890	15,022 Added 21.2%	85,865 $1.26 Million
Q4 2021 Feb 14, 2022	SELL	$19.29 - $31.51 $270,330 - $441,581	-14,014 Reduced 16.51%	70,843 $1.43 Million
Q3 2021 Nov 15, 2021	BUY	$20.45 - $30.0 $1.74 Million - $2.55 Million	84,857 New	84,857 $2.3 Million

Others Institutions Holding ADCT

# of Institutions

Shares Held

53.9M

Call Options Held

Put Options Held

7.6K

View Full List

About ADC Therapeutics SA

Ticker ADCT
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,645,296
Market Cap $267M
Description
ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma;...

More about ADCT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account